Gene Editing Therapeutics Market to Hit $6.26B by 2032, Fueled by CRISPR Breakthroughs
Event summary
- The Gene Editing Therapeutics Market is projected to reach $6.26B by 2032, up from $11.13M in 2024, at a CAGR of 147.20%.
- The FDA approved the first CRISPR-based gene-editing therapy, Casgevy, in 2023 for treating sickle cell disease.
- Over 200 CRISPR-based clinical trials are currently underway globally, targeting more than 50 different diseases.
- Vertex Pharmaceuticals holds an 82.20% market share, driven by its CRISPR/Cas9-based therapy CASGEVY™.
The big picture
The Gene Editing Therapeutics Market is experiencing explosive growth, driven by breakthroughs in CRISPR technology and supportive regulatory environments. The market's expansion is underpinned by the transition of gene-editing technologies from experimental labs to real-world clinical applications, with significant investments and research initiatives accelerating commercialization. The ability to provide durable, single-dose treatments that eliminate the need for lifelong medication is expected to significantly improve patient outcomes while reducing long-term healthcare burdens.
What we're watching
- Regulatory Support
- How the streamlined regulatory review processes will affect the pace of market adoption of gene editing therapeutics globally.
- Technological Advancements
- Whether next-generation gene-editing technologies like base editing can sustain the current growth momentum.
- Market Consolidation
- The pace at which smaller players can challenge the dominance of Vertex Pharmaceuticals and Bluebird Bio in the gene editing therapeutics market.
Related topics